Home
News
Screeners
Insights
Sai Parenteral's
523.
65
-5.65
(-1.07%)
Market Cap
₹2,313.45 Cr
PE Ratio
112.50
Industry
Healthcare
Buy
Sell
Company Performance:
1D
-1.07%
1M
+0.44%
6M
+29.07%
1Y
+29.07%
5Y
+29.07%
View Company Insights
Latest news about Sai Parenteral's
Sai Parenterals to host investor meet in Hyderabad on Oct 14
20 hrs ago
Yesterday
Sai Parenterals Ltd will hold an investor meeting on October 14, 2026. The event starts at 11:00 am at the company's Hyderabad facilities. Discussions will be limited to publicly available information only. No unpublished price sensitive information (UPSI) will be disclosed.
Sai Parenterals appoints new CS and COO after officer resignation
2 days ago
Sai Parenterals shareholders approve all 12 AGM resolutions despite ESOP dissent
Sep 10, 2026
Sai Parenteral wins Rs 204 crore order from Australia pharmacy chain
Aug 25, 2026
Sai Parenterals hosts analyst meet on August 31 in Mumbai
Aug 25, 2026
More news about Sai Parenteral's
20
Aug 26
Sai Parenterals redirects ₹1,018.57 crore IPO funds for M&A
Sai Parenterals Limited proposes to utilise ₹1,018.57 million of unutilised IPO proceeds to acquire 60% stakes in Saicriti Pharma and Prathyak Laboratories. This strategic shift replaces organic expansion plans due to regulatory constraints under the Hyderabad Industrial Lands Transformation Policy. The move aims to secure immediate manufacturing capacity and R&D capabilities while navigating urban relocation mandates.
18
Aug 26
Sai Parenterals profit jumps 975% in Q1FY27; approves stake acquisitions
Sai Parenterals Limited posted a 975% YoY profit jump to ₹8.9 crore in Q1FY27, driven by 175% revenue growth to ₹52.8 crore. Consolidated revenue hit ₹182.4 crore. The Board approved redirecting IPO funds to acquire 60% stakes in Saicriti Pharma and Prathyak Laboratories to boost capacity and R&D, while maintaining FY27 guidance of ₹750 crore revenue.
12
Aug 26
Sai Parenterals Q1 Results: ₹571 Cr Capex Plan, Noumed Integration
Sai Parenterals Limited reported a consolidated net profit before tax of ₹11.9 crore for FY26, with operating cash flow rising to ₹98.0 crore. The company announced a ₹571 crore capex plan, including the proposed acquisition of Saicriti Pharma and Prathyak Laboratories, funded by varied IPO proceeds. Consolidation of Noumed Pharmaceuticals from November 2025 makes year-on-year comparisons non-like-for-like.
07
Jul 26
Sai Parenterals appoints auditors for FY27 and authorizes growth
Sai Parenterals Limited appointed M/s. Aakanksha Dubey & Co. as Secretarial Auditors for 2026-27 to 2030-31, subject to shareholder approval. The board also appointed M/s. NSVR & Associates LLP as Internal Auditors and M/s. Sai Krishna & Associates as Cost Auditors for FY 2026-27. Additionally, Mr. Anil Kumar Karusala was authorized to explore organic and inorganic growth opportunities.
02
Jul 26
Sai Parenterals subsidiary wins AUD 202 Mn OTC order
Sai Parenterals Limited's subsidiary Noumed Pharmaceuticals Pty Limited has entered into an exclusive Over-The-Counter (OTC) medicine supply agreement with Australia’s leading pharmacy network. The contract, valued at AUD 202 Million (INR 1300 crores), is effective from July 1, 2026, for an initial term of 7.5 years, extendable by 3 years. The international transaction is not a related party transaction and was disclosed in compliance with SEBI LODR Regulations.
01
Jul 26
Sai Parenterals to host virtual analyst meet on Jul 2
Sai Parenteral's Limited will conduct a virtual analyst and institutional investor meeting on July 2, 2026, hosted by Axis Capital. The session, scheduled from 10:00 AM to 11:00 AM IST, will focus on business performance and outlook without sharing unpublished price sensitive information.
30
May 26
Sai Parenterals targets ₹750 crore revenue in FY27
Sai Parenterals Limited reported a 133% year-on-year growth in consolidated revenue to ₹381 crore for FY26, following the acquisition of Noumed Pharmaceuticals. The company has provided guidance for FY27, targeting a revenue of ₹750 crore with an EBITDA margin of 17%, supported by long-term contracts and vertical integration. A capital expenditure program of ₹440 crore is underway, with full benefits expected in FY28.
29
May 26
Sai Parenterals secures $11 million anti-TB supply order
Sai Parenterals Limited has secured purchase orders worth USD 11 million (₹104.50 crore) from PILL CORP Philippines for the exclusive supply of anti-TB products. The 10-year contract, effective June 1, 2026, is not a related party transaction, and no promoters hold interest in the client.
28
May 26
Sai Parenterals FY26 PAT rises 45.5% to ₹14.37 Cr
Sai Parenterals reported FY26 PAT of ₹14.37 crore, up 45.5%, driven by CDMO exports and the Noumed acquisition. Consolidated revenue surged 140.4% to ₹380.99 crore.
Sai Parenteral's
523.
65
-
5.
65
(-
1.
07
%)
1 Year Returns:
+29.07%
Industry Peers
Sun Pharmaceutical
1,801.00
(-
0.
86
%)
Divis Laboratories
9,249.00
(-
0.
46
%)
Torrent Pharmaceuticals
4,767.30
(-
0.
68
%)
Zydus Life Science
1,145.70
(-
1.
40
%)
Cipla
1,344.00
(-
0.
15
%)
Laurus Labs
1,984.00
(+
0.
20
%)
Mankind Pharma
2,535.00
(+
1.
25
%)
Dr Reddys Laboratories
1,206.20
(-
2.
17
%)
Aurobindo Pharma
1,676.80
(+
0.
29
%)
Lupin
2,031.20
(+
0.
05
%)
Get More Market Insights with
Heatmap
FII/DII
Company Filings
MF Holdings
Bulk/ Block Deals
Stock Rental via SLBM
Signals
MTF Insights
F&O Ban - MWPL
Top Deliveries
Market Valuation
IPO
Cyclical Trend
Events Calendar